Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 1 of 77
`Case 1:22-cv-02229-MKV Document1-9 Filed 03/18/22 Page 1 of 77
`
`
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT I
`EXHIBIT I
`
`
`
`

`

`( 12 ) United States Patent
`Yaworski et al .
`
`US 11,141,378 B2
`( 10 ) Patent No .:
`( 45 ) Date of Patent :
`* Oct . 12 , 2021
`
`US011141378B2
`
`( 72 )
`
`( 54 ) LIPID FORMULATIONS FOR NUCLEIC
`ACID DELIVERY
`( 71 ) Applicant : ARBUTUS BIOPHARMA
`CORPORATION , Vancouver ( CA )
`Inventors : Edward Yaworski , Maple Ridge ( CA ) ;
`Kieu Lam , Surrey ( CA ) ; Lloyd Jeffs ,
`Delta ( CA ) ; Lorne Palmer , Vancouver
`( CA ) ; Ian MacLachlan , Mission ( CA )
`( 73 ) Assignee : ARBUTUS BIOPHARMA
`CORPORATION , Vancouver ( CA )
`Subject to any disclaimer , the term of this
`patent is extended or adjusted under 35
`U.S.C. 154 ( b ) by 0 days .
`This patent is subject to a terminal dis
`claimer .
`( 21 ) Appl . No .: 17 / 227,802
`Apr. 12 , 2021
`( 22 ) Filed :
`( 65 )
`Prior Publication Data
`Sep. 2 , 2021
`US 2021/0267895 A1
`
`( * ) Notice :
`
`( 63 )
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 2 of 77
`
`Related U.S. Application Data
`Continuation of application No. 17 / 094,724 , filed on
`Nov. 10 , 2020 , which is a continuation of application
`No. 16 / 422,441 ,
`filed on May 24 , 2019 , now
`abandoned , which is a continuation of application No.
`15 / 840,933 , filed on Dec. 13 , 2017 , now abandoned ,
`which is
`continuation of application No.
`a
`15 / 670,742 , filed on Aug. 7 , 2017 , now abandoned ,
`which is
`continuation of application No.
`15 / 164,803 , filed on May 25 , 2016 , now abandoned ,
`which is
`continuation of application No.
`a
`14 / 462,441 , filed on Aug. 18 , 2014 , now Pat . No.
`9,364,435 , which is a continuation of application No.
`13 / 928,309 , filed on Jun . 26 , 2013 , now Pat . No.
`8,822,668 , which is a continuation of application No.
`13 / 253,917 , filed on Oct. 5 , 2011 , now Pat . No.
`8,492,359 , which is a continuation of application No.
`a
`12 / 424,367 , filed on Apr. 15 , 2009 , now Pat . No.
`8,058,069 .
`
`a
`
`2
`
`( 60 ) Provisional application No. 61 / 045,228 , filed on Apr.
`15 , 2008 .
`( 51 ) Int . Cl .
`CO7H 21/02
`CO7H 21/04
`A61K 9/127
`A61K 48/00
`CO7H 21/00
`C07 ) 9/00
`C12N 15/113
`A61K 31/713
`C12N 15/11
`
`( 2006.01 )
`( 2006.01 )
`( 2006.01 )
`( 2006.01 )
`( 2006.01 )
`( 2006.01 )
`( 2010.01 )
`( 2006.01 )
`( 2006.01 )
`
`( 52 ) U.S. CI .
`CPC
`
`A61K 9/1272 ( 2013.01 ) ; A61K 9/1271
`( 2013.01 ) ; A61K 31/713 ( 2013.01 ) ; A61K
`48/0025 ( 2013.01 ) ; C07H 21/00 ( 2013.01 ) ;
`CO7J 9/00 ( 2013.01 ) ; C12N 15/111 ( 2013.01 ) ;
`C12N 15/113 ( 2013.01 ) ; C12N 15/1137
`( 2013.01 ) ; C12N 2310/14 ( 2013.01 ) ; C12N
`2320/32 ( 2013.01 )
`
`( 58 ) Field of Classification Search
`CPC
`C12N 15/113
`See application file for complete search history .
`
`( 56 )
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`4,394,448 A
`4,438,052 A
`4,515,736 A
`4,598,051 A
`4,897,355 A
`5,013,556 A
`5,171,678 A
`5,208,036 A
`5,225,212 A
`5,264,618 A
`5,279,833 A
`5,283,185 A
`5,320,906 A
`5,334,761 A
`5,545,412 A
`5,578,475 A
`5,627,159 A
`5,641,662 A
`
`7/1983 Szoka , Jr. et al .
`3/1984 Weder et al .
`5/1985 Deamer
`7/1986 Papahadjopoulos et al .
`1/1990 Eppstein et al .
`5/1991 Woodle et al .
`12/1992 Behr et al .
`5/1993 Eppstein et al .
`7/1993 Martin et al .
`11/1993 Felgner et al .
`1/1994 Rose
`2/1994 Epand et al .
`6/1994 Eley et al .
`8/1994 Gebeyehu et al .
`8/1996 Eppstein et al .
`11/1996 Jessee
`5/1997 Shih et al .
`6/1997 Debs et al .
`( Continued )
`FOREIGN PATENT DOCUMENTS
`
`CA
`CA
`
`4/1999
`2309727 A1
`11/1999
`2271582 A1
`( Continued )
`
`OTHER PUBLICATIONS
`Basarkar et al . ( Int J Nanomedicine , 2007 , 2 ( 3 ) , 353-360 ) . *
`( Continued )
`
`Primary Examiner Amy H Bowman
`( 74 ) Attorney , Agent , or Firm Kilpatrick Townsend &
`Stockton LLP
`
`ABSTRACT
`( 57 )
`The present invention provides novel , stable lipid particles
`comprising one or more active agents or therapeutic agents ,
`methods of making the lipid particles , and methods of
`delivering and / or administering the lipid particles . More
`particularly , the present invention provides stable nucleic
`acid - lipid particles ( SNALP ) comprising a nucleic acid
`( such as one or more interfering RNA ) , methods of making
`the SNALP , and methods of delivering and / or administering
`the SNALP .
`
`30 Claims , 24 Drawing Sheets
`Specification includes a Sequence Listing .
`
`

`

`US 11,141,378 B2
`Page 2
`
`( 56 )
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`5,656,743 A
`5,674,908 A
`5,703,055 A
`5,705,385 A
`5,736,392 A
`5,753,613 A
`5,820,873 A
`5,877,220 A
`5,885,613 A
`5,958,901 A
`5,976,567 A
`5,981,501 A
`6,020,202 A
`6,020,526 A
`6,034,135 A
`6,051,429 A
`6,075,012 A
`6,165,501 A
`6,172,049 B1
`6,251,939 B1
`6,284,267 B1
`6,287,591 B1
`6,339,173 B1
`6,376,248 B1
`6,534,484 B1
`6,586,410 B1
`6,638,529 B2
`6,649,780 B1
`6,671,393 B2
`6,696,424 B1
`6,815,432 B2
`6,858,224 B2
`7,166,745 B1
`7,422,902 B1
`7,479,573 B2
`7,491,409 B1
`7,601,872 B2
`7,687,070 B2
`7,745,651 B2
`7,799,565 B2
`7,803,397 B2
`7,807,815 B2
`7,838,658 B2
`7,901,708 B2
`7,915,450 B2
`7,939,505 B2
`7,982,027 B2
`8,058,068 B2
`8,058,069 B2
`8,101,741 B2
`8,158,601 B2
`8,158,827 B2
`8,188,263 B2
`8,227,443 B2
`8,236,943 B2
`8,283,333 B2
`8,455,455 B1
`8,466,122 B2
`8,492,359 B2
`8,513,403 B2
`8,569,256 B2
`8,598,333 B2
`8,716,464 B2
`8,822,668 B2
`8,865,675 B2
`8,999,950 B2
`9,006,191 B2
`9,006,417 B2
`9,018,187 B2
`9,035,039 B2
`9,126,966 B2
`9,139,554 B2
`9,187,748 B2
`9,364,435 B2
`9,404,127 B2
`
`8/1997 Busch et al .
`10/1997 Haces et al .
`12/1997 Felgner et al .
`1/1998 Bally et al .
`4/1998 Hawley - Nelson et al .
`5/1998 Ansell et al .
`10/1998 Choi et al .
`3/1999 Schwartz et al .
`3/1999 Holland et al .
`9/1999 Dwyer et al .
`11/1999 Wheeler et al .
`11/1999 Wheeler et al .
`2/2000 Jessee
`2/2000 Schwartz et al .
`3/2000 Schwartz et al .
`4/2000 Hawley - Nelson et al .
`6/2000 Gebeyehu et al .
`12/2000 Tirosh et al .
`1/2001 Dwyer et al .
`6/2001 Schwartz et al .
`9/2001 Aneja
`9/2001 Semple et al .
`1/2002 Schwartz et al .
`4/2002 Hawley - Nelson et al .
`3/2003 Wheeler et al .
`7/2003 Wheeler et al .
`10/2003 Schwartz et al .
`11/2003 Eibl et al .
`12/2003 Hays et al .
`2/2004 Wheeler et al .
`11/2004 Wheeler et al .
`2/2005 Wheeler et al .
`1/2007 Chu et al .
`9/2008 Wheeler et al .
`1/2009 Chu et al .
`2/2009 Meers et al .
`10/2009 Chu et al .
`3/2010 Gebeyehu et al .
`6/2010 Heyes et al .
`9/2010 MacLachlan et al .
`9/2010 Heyes et al .
`10/2010 MacLachlan et al .
`11/2010 MacLachlan et al .
`3/2011 MacLachlan et al .
`3/2011 Chu et al .
`5/2011 Quay et al .
`7/2011 MacLachlan et al .
`11/2011 Hawley - Nelson et al .
`11/2011 Yaworski et al .
`1/2012 MacLachlan et al .
`4/2012 Chen et al .
`4/2012 Chu et al .
`5/2012 MacLachlan et al .
`7/2012 MacLachlan et al .
`8/2012 Lee et al .
`10/2012 Yaworski et al .
`6/2013 Robbins et al .
`6/2013 Heyes et al .
`7/2013 Yaworski et al .
`8/2013 MacLachlan et al .
`10/2013 Heyes et al .
`12/2013 MacLachlan et al .
`5/2014 Geisbert et al .
`9/2014 Yaworski et al .
`10/2014 Heyes et al .
`4/2015 MacLachlan et al .
`4/2015 MacLachlan et al .
`4/2015 Yaworski et al .
`4/2015 Heyes et al .
`5/2015 Dhillon et al .
`9/2015 Martin et al .
`9/2015 Hope et al .
`11/2015 Geisbert et al .
`6/2016 Yaworski et al .
`8/2016 Yaworski et al .
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 3 of 77
`
`9,504,651 B2
`9,518,272 B2
`9,878,042 B2
`10,053,689 B2
`10,077,232 B2
`10,415,037 B2
`2001/0048940 A1
`2003/0069173 Al
`2003/0072794 Al
`2003/0077829 A1
`2003/0143732 A1
`2004/0063654 Al
`2004/0142892 Al
`2004/0253723 A1
`2004/0259247 A1
`2005/0064595 A1
`2005/0118253 Al
`2005/0260757 A1
`2006/0008910 Al
`2006/0134189 Al
`2006/0147514 A1
`2006/0228406 A1
`2006/0240093 Al
`2006/0240554 Al
`2007/0042031 A1
`2007/0135372 Al
`2007/0202598 A1
`2007/0202600 A1
`2008/0020058 Al
`2008/0317839 A1
`2009/0143583 Al
`2009/0291131 A1
`2010/0130588 Al
`2010/0159593 Al
`2011/0076335 Al
`2012/0058188 Al
`2012/0136073 Al
`2012/0183581 A1
`2012/0238747 Al
`2013/0116307 A1
`2013/0122104 Al
`2013/0303587 Al
`2014/0065228 Al
`2014/0294937 A1
`2015/0164799 A1
`2015/0374834 Al
`2016/0032320 A1
`2016/0251681 Al
`2017/0042814 A1
`2017/0260523 A1
`2017/0307608 A1
`2018/0071397 A1
`2018/0085312 Al
`2018/0092848 Al
`2019/0032051 A1
`2019/0240339 Al
`2020/0113832 Al
`2021/0207140 A1
`2021/0220274 A1
`
`11/2016 MacLachlan et al .
`12/2016 Yaworski et al .
`1/2018 Yaworski et al .
`8/2018 Fitzgerald et al .
`9/2018 Heyes et al .
`9/2019 Cross et al .
`12/2001 Tousignant et al .
`4/2003 Hawley - Nelson et al .
`4/2003 Boulikas
`4/2003 MacLachlan
`7/2003 Fosnaugh et al .
`4/2004 Davis et al .
`7/2004 Finn et al .
`12/2004 Tachas et al .
`12/2004 Tuschi et al .
`3/2005 MacLachlan et al .
`6/2005 MacLachlan et al .
`11/2005 Gebeyehu et al .
`1/2006 MacLachlan et al .
`6/2006 MacLachlan et al .
`7/2006 Gebeyehu et al .
`10/2006 Chiou et al .
`10/2006 MacLachlan et al .
`10/2006 Chen et al .
`2/2007 MacLachlan et al .
`6/2007 MacLachlan et al .
`8/2007 Chu et al .
`8/2007 Chu et al .
`1/2008 Chen et al .
`12/2008 Quay et al .
`6/2009 Chu et al .
`11/2009 MacLachlan et al .
`5/2010 Yaworski et al .
`6/2010 Chu et al .
`3/2011 Yaworski et al .
`3/2012 MacLachlan et al .
`5/2012 Zhiwei et al .
`7/2012 Yaworski et al .
`9/2012 Chu et al .
`5/2013 Heyes et al .
`5/2013 Yaworski et al .
`11/2013 Yaworski et al .
`3/2014 Yaworski et al .
`10/2014 MacLachlan et al .
`6/2015 Yaworski et al .
`12/2015 Yaworski et al .
`2/2016 Yaworski et al .
`9/2016 Yaworski et al .
`2/2017 Yaworski et al .
`9/2017 Yaworski et al .
`10/2017 Bettencourt
`3/2018 Yaworski et al .
`3/2018 Yaworski et al .
`4/2018 Yaworski et al .
`1/2019 Yaworski et al .
`8/2019 Yaworski et al .
`4/2020 Yaworski et al .
`7/2021 Yaworski et al .
`7/2021 Yaworski et al .
`
`FOREIGN PATENT DOCUMENTS
`
`C12N 15/113
`
`CA
`CA
`CA
`CA
`EP
`EP
`JP
`JP
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`WO
`WO
`
`2330741 A1
`2397016 A1
`2513623
`2637931
`1 648 519 B1
`2 567 693 B1
`03-126211
`05-202085
`06-080560
`2002-525063
`2003-505401
`2007-524349
`91/16024 A1
`93/05162 A1
`93/12240 A1
`93/12756 A2
`93/24640 A2
`
`11/1999
`7/2001
`8/2004
`7/2007
`10/2014
`10/2015
`5/1991
`8/1993
`3/1994
`8/2002
`2/2003
`8/2007
`10/1991
`3/1993
`6/1993
`7/1993
`12/1993
`
`

`

`> >
`
`> >
`
`US 11,141,378 B2
`Page 3
`
`( 56 )
`
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`References Cited
`FOREIGN PATENT DOCUMENTS
`
`93/25673 A1
`95/02698 A1
`95/18863 A1
`95/35301 A1
`96/02655 A1
`96/10390 A1
`96/40964 A2
`96/41873 A1
`98/51285 A2
`00/03683 A2
`00/15820 A1
`00/62813 A2
`01/05374 A1
`01/05873 A1
`01/75164 A2
`01/93836
`02/034236 A2
`02/087541 A1
`03/097805 A2
`2004/065546 A2
`2004/110499 Al
`2005/007196 A2
`2005/026372 A1
`2005/035764 A1
`2005/120152 A2
`2006/002538 Al
`2006/053430 A1
`2007/056861 Al
`2009/086558 Al
`2009/111658 A2
`2010/042877 A1
`2010/048228 A2
`2010/088537 A2
`2010/105209 A1
`2013/090648 A1
`2017/223135 Al
`2018/232357 Al
`
`12/1993
`1/1995
`7/1995
`12/1995
`2/1996
`4/1996
`12/1996
`12/1996
`11/1998
`1/2000
`3/2000
`10/2000
`1/2001
`1/2001
`10/2001
`12/2001
`5/2002
`11/2002
`11/2003
`8/2004
`12/2004
`1/2005
`3/2005
`4/2005
`12/2005
`1/2006
`5/2006
`5/2007
`7/2009
`9/2009
`4/2010
`4/2010
`8/2010
`9/2010
`6/2013
`12/2017
`12/2018
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 4 of 77
`
`OTHER PUBLICATIONS
`Shimada et al . ( International Journal of Pharmaceutics , 203 , 2000 ,
`255-263 ) . *
`Gallie ( Plant Cell Reports , 1993 , 13 , 119-122 ) *
`Semple et al . ( Biochemistry , 1996 , 35 , 2521-2525 ) . *
`Li et al . ( Trends in Pharmacological Sciences , 23 , 5 , 2002 , 206
`209 ) . *
`Arima et al . ( Biomaterials , 29 , 2008 , 551-560 ) . *
`Ahmad , A. et al . , “ New multivalent cationic lipids reveal bell curve
`for transfection efficiency versus membrane charge density : lipid
`DNA complexes for gene delivery , ” J. Gene Med . , 7 ( 6 ) : 739-48 ,
`2005 .
`Akinc , A. et al . , “ The Onpattro story and the clinical translation of
`nanomedicines containing nucleic acid - based drugs , ” Nature Nano
`technology , 14 : 1084-1087 , 2019 .
`Alnylam Pharmaceuticals , Inc. , ONPATTRO Label , Revised Aug.
`2018 .
`Ambegia , E. et al . ,
`“ Stabilized plasmid - lipid particles containing
`PEG - diacylglycerols exhibit extended circulation lifetimes and tumor
`selective gene expression , ” Biochimica et Biophysica Acta , 1669 : 155
`163 , 2005 .
`Arbutus Biopharma Corporation , “ Arbutus ' LNP Licensee Alnylam
`Announces FDA Approval of ONPATTROTM ( patisiran ) , for the
`Treatment of ATTR Amyloidosis , ” Press Release , https : // investor .
`arbutusbio.com/news-releases/news-release-details/arbutus-Inp
`licensee - alnylam - announces - fda - approval - onpattrotm , Aug. 13 , 2018 ,
`2 pages .
`Arpicco , S. et al . , “ Preparation and characterization of novel cationic
`lipids developed for gene transfection , ” Proceed . Int'l Symp . Con
`trol . Rel . Bioact . Mater . ( Controlled Release Society , Inc. ) , 26 : 759
`760 , 1999 .
`
`> >
`
`Arpicco , S. et al . , “ Synthesis , characterization and transfection
`activity of new saturated and unsaturated cationic lipids , ” IL Farmaco ,
`59 : 869-878 , 2004 .
`Bahl , K. et al . , " Preclinical and Clinical Demonstration of Immunogenic
`ity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , "
`Molecular Therapy , 25 ( 6 ) : 1316-1327 , 2017 .
`Ballas , N. et al . , “ Liposomes bearing a quaternary ammonium
`detergent as an efficient vehicle for functional transfer of TMV
`RNA into plant protoplasts , ” Biochimica et Biophysica Acta , 939 : 8
`18 , 1988 .
`Barinaga , M. , “ Step taken toward improved vectors for gene trans
`fer , ” Science , 266 : 1326 , 1994 .
`Bass , B. “ The short answer , ” Nature , 411 : 428-429 , 2001 .
`Beale , G. et al . , “ Gene silencing nucleic acids designed by scanning
`arrays : Anti - EGFR activity of siRNA , ribozyme and DNA enzymes
`targeting a single hybridization - accessible region using the same
`delivery system , ” Journal of Drug Targeting , 11 ( 7 ) : 449-456 , 2003 .
`Behr , J. , " Synthetic gene - transfer vectors , ” Acc . Chem . Res . , 26 : 274
`278 , 1993 .
`Bennett et al . , “ Cholesterol enhances cationic liposome - mediated
`DNA transfection of human respiratory epithelial cells , ” Bioscience
`Reports , 15 : 47-53 , 1995 .
`Brigham , K. et al . ,
`“ Rapid communication : In vivo transfection of
`murine lungs with a functioning prokaryotic gene using a liposome
`vehicle , ” The American Journal of the Medical Sciences , 298 ( 4 ) : 278
`281 , 1989 .
`Brummelkamp , T. et al . , “ A system for stable expression of short
`interfering RNAs in mammalian cells . ” Science , 296 : 550-553 ,
`2002 .
`Cevc , G. , “ How membrane chain - melting phase - transition tempera
`ture is affected by the lipid chain asymmetry and degree of unsatura
`tion : an effective chain - length model , ” Biochemistry , 30 : 7186
`7193 , 1991 .
`Check , E. ,
`“ RNA to the Rescue ? Disease therapies based on a
`technique for gene silencing called RNA interference are racing
`towards the clinic . Erika Check investigates molecular medicine's
`next big thing , ” Nature , 425 : 10-12 , 2003 .
`Chonn , A. et al . , “ Recent advances in liposomal drug - delivery
`systems , ” Current Opinion in Biotechnology , 6 : 698-708 , 1995 .
`Cortesi , R. et al . , “ Effect of cationic liposome composition on in
`vitro cytotoxicity and protective effect on carried DNA , ” Interna
`tional Journal of Pharmaceutics , 139 : 69-78 , 1996 .
`Crystal , R. ,
`“ Transfer of genes to humans : early lessons and
`obstacles to success , ” Science , 270 : 404-410 , 1995 .
`Culver , K. ,
`“ The first human gene therapy experiment , ” Gene
`Therapy : A Handbook for Physicians , 1994 , pp . 33-40 .
`Duzgunes , N. , “ Membrane fusion , ” Subcellular Biochemistry , 11 : 195
`286 , 1985 .
`Dwarki , V. et al . , " Cationic liposome - mediated RNA transfection , "
`Methods in Enzymology , 217 : 644-654 , 1993 .
`Elbashir , S. et al . , “ Duplexes of 21 - nucleotide RNAs mediate RNA
`interference in cultured mammalian cells , ” Nature , 411 : 494-498 ,
`2001 .
`Enoch , H. et al . , “ Formation and properties of 1000 - Å - diameter ,
`single - bilayer phospholipid vesicles , ” Proc . Natl . Acad . Sci . USA ,
`76 ( 1 ) : 145-149 , 1979 .
`European Medicines Agency , “ New Medicine for Hereditary Rare
`Disease , ” Press Release , https://www.ema.europa.eu/en/news/new
`medicine - hereditary - rare - disease , Jul . 27 , 2018 , 2 pages .
`Felgner , J. et al . ,
`“ Cationic lipid - mediated transfection in mamma
`lian cells : ‘ Lipofection , " J. Tiss . Cult . Meth . , 15 : 63-68 , 1993 .
`Felgner , J. et al . ,
`“ Enhanced gene delivery and mechanism studies
`with a novel series of cationic lipid formulations , ” The Journal of
`Biological Chemistry , 269 ( 4 ) : 2550-2561 , 1994 .
`Felgner , P. et al . ,
`" Cationic liposome mediated transfection , ” Proc .
`West . Pharmacol . Soc . , 32 : 115-121 , 1989 .
`Felgner , P. et al . ,
`“ Lipofection : A highly efficient , lipid - mediated
`DNA - transfection procedure , ” Proc . Natl . Acad . Sci . USA , 84 : 7413
`7417 , 1987 .
`Filion , M.C. and Phillips , N.C. ,
`“ Toxicity and immunomodulatory
`activity of liposomal vectors formulated with cationic lipids towards
`immune effector cells , ” Biochim . Biophys . Acta . , 1329 ( 2 ) : 345-356 ,
`1997 .
`
`>
`
`> >
`
`)
`
`

`

`US 11,141,378 B2
`Page 4
`
`( 56 )
`
`References Cited
`OTHER PUBLICATIONS
`“ A novel cationic liposome reagent for efficient
`Gao , X. et al . ,
`transfection of mammalian cells , ” Biochem . Biophys . Res . Comm . ,
`179 ( 1 ) : 280-285 , 1991 .
`Gao , X. et al . , “ Nonviral gene Delivery : What we know and what
`is next , ” AAPS Journal , 9 ( 1 ) : E92-104 , 2007 .
`Gershon , H. et al . , “ Mode of formation and structural feature of
`DNA - cationic liposome complexes used for transfection , ” Biochem
`istry , 32 : 7143-7151 , 1993 .
`Global Newswire , retrieved from http://globalnewswire.com on
`Feb. 27 , 2013 , Tekmira sues Alnylam Pharmaceuticals for repeated
`misuse of trade secrets and confidential information , Mar. 16 , 2011 ,
`pp . 1-3 .
`Guy - Caffey , J. et al . ,
`“ Novel polyami nolipids enhance the cellular
`uptake of oligonucleotides , ” The Journal of Biological Chemistry ,
`270 ( 52 ) : 31391-31396 , 1995 .
`Hausseker , D. , “ The Business of RNAi Therapeutics in 2012 , " Molecu
`lar Therapy - Nucleic Acids , 2 : e8 , 2012 , 12 pages .
`Hawley - Nelson , P. et al . , “ LipofectAmineTM reagent : a new , higher
`efficiency polycationic liposome transfection reagent , ” Focus , 15 ( 3 ) : 73
`80 , 1993 .
`Heyes , J. et al . ,
`" Cationic lipid saturation influences intracellular
`delivery of encapsulated nucleic acids , ” Journal of Controlled
`Release , 107 : 276-287 , 2005 .
`Heyes , J. et al . , " Synthesis of novel cationic lipids : effect of
`structural modification on the efficiency of gene transfer , " J. Med .
`Chem . , 45 : 99-114 , 2002 .
`Huang , L. et al . , “ Liposomal Gene Delivery : A Complex Package , ”
`Nature Biotechnology , 15 : 620-621 , 1997 .
`Hyde , S. et al . , “ Correction of the ion transport defect in cystic
`fibrosis transgenic mice by gene therapy , ” Nature , 362 : 250-255 ,
`1993 .
`Janoff , A. , “ Declaration of Andrew S. Janoff , Ph.D. in support of
`Moderna Therapeutics , Inc.'s Petition for Inter Partes Review of
`U.S. Pat . No. 9,364,435 , ” Inter Partes Review of U.S. Pat . No.
`9,364,435 B2 , Case No. IPR2018-00739 , filed Mar. 5 , 2018 , 69
`pages .
`Jiang , L. et al . , “ Comparison of protein precipitation methods for
`sample preparation prior to proteomic analysis , ” Journal of Chro
`matography A , 1023 : 317-320 , 2004 .
`Juliano , R. et al . , “ The effect of particle size and charge on the
`clearance rates of liposomes and liposome encapsulated drugs , "
`Biochem . Biophys . Res . Commun . , 63 ( 3 ) : 651-658 , 1975 .
`Kauffman , K. et al . ,
`" Optimization of Lipid Nanoparticle Formu
`lations for mRNA Delivery in Vivo with Fractional Factorial and
`Definitive Screening Designs , " Nano Letters , 15 ( 11 ) : 7300-7306 ,
`2015 .
`Keough , K. , “ Influence of chain unsaturation and chain position on
`thermotropism and intermolecular interactions in membranes , ” Biochem .
`Soc . Transactions , 18 ( 5 ) : 835-837 , 1990 .
`Krichevsky , A. et al . ,
`“ RNAi functions in cultured mammalian
`neurons , ” PNAS , 99 ( 18 ) : 11926-29 , 2002 .
`Lawrence , M. et al . “ The formation , characterization and stability of
`non - ionic surfactant vesicles , ” S.T.P. Pharma Sciences , 6 ( 1 ) : 49-60 ,
`1996 .
`Lawrence , M. et al . ,
`“ Synthesis and aggregation properties of
`dialkyl polyoxyethylene glycerol ethers , " Chemistry and Physics of
`Lipids , 82 ( 2 ) : 89-100 , 1996 .
`Ledford , H. , “ Gene - Silencing Drug Approved : US Government
`Okays First RNA - Interference Drug After a 20 - Year Wait , ” Nature ,
`560 : 291-292 , 2018 .
`Legendre , J.-Y. et al . , “ Delivery of plasmid DNA into mammalian
`cell lines using pH - sensitive liposomes : comparison with cationic
`liposomes , ” Pharm . Res . , 9 ( 10 ) : 1235-42 , 1992 .
`Leventis , R. et al . , “ Interactions of mammalian cells with lipid
`dispersions containing novel metabolizable cationic amphiphiles , "
`Biochem . Biophys . Acta , 1023 : 124-132 , 1990 .
`Li and Szoka , “ Lipid - based nanoparticles for nucleic acid delivery , "
`Pharmaceutical Research , 2483 : 438-449 , 2007 .
`
`> >
`
`>
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 5 of 77
`
`> >
`
`2
`
`> >
`
`Lin , A.J. et al . , “ Three - dimensional imaging of lipid gene - carriers :
`Membrane charge density controls universal transfection behavior
`in lamellar cationic liposome - DNA complexes , ” Biophys J. , 84 ( 5 ) : 3307
`16 , 2003 .
`Liu , Y. et al . , “ Cationic liposome - mediated intravenous gene deliv
`ery ” , J. Biol . Chem . , 270 : 24864-70 , 1995 .
`MacLachlan , “ Liposomal Formulations for Nucleic Acid Delivery , "
`Antisense Drug Technologies , Second Edition ; 2007 ; pp . 237-270 .
`MacLachlan , I. and Cullis , P. , “ Diffusible - PEG - Lipid Stabilized
`Plasmid Lipid Particles , ” Advances in Genetics , 53 : 157-188 , 2005 .
`Marshall , E. , “ Gene therapy's growing pains , ” Science , 269 : 1050
`1055 , 1995 .
`Middaugh , C. and Ramsey , C. , “ Analysis of Cationic - Lipid - Plasmid
`DNA Complexes , ” Analytical Chemistry , American Chemical Soci
`ety , 2007 , pp . 7240-7248 .
`Murahashi , N. et al . , “ Synthesis and application of neoglycolipid for
`liposome modification , ” Biol . Pharm . Bull . , 20 ( 6 ) : 704-707 , 1997 .
`Orkin , S. et al . , NIH Report , Report and Recommendations of the
`Panel to Assess the NIH Investment in Research on Gene Therapy ,
`1995 , 41 pages .
`Ortho Biotech Products , LP , “ Doxil® Label Product Insert , Revised
`May 2007 , ” https://www.accessdata.fda.gov/drugsatfda_docs/label/
`2007 / 050718s0291bl.pdf , 33 pages .
`Pak , C. et al . , “ Elastase - activated liposomal delivery to nucleated
`cells , ” Biochimica et Biophysica Acta , 1419 : 111-126 , 1999 .
`Parr , M. et al . , “ Factors influencing the retention and chemical
`stability of polly ( ethylene glycol ) -lipid conjugates incorporated into
`large unilamellar vesicles , ” Biochimica et Biophysica Acta , 1195 : 21
`30 , 1994 .
`Paul , C. et al . , “ Effective expression of small interfering RNA in
`human cells , ” Nature Biotech . , 20 : 505-508 , 2002 .
`Puyal , C. et al . , “ A new cationic liposome encapsulating genetic
`material : A potential delivery system for polynucleotides , ” Eur . J.
`Biochem . , 228 : 697-703 , 1995 .
`Sawada , K. et al . ,
`“ Microemulsions in supercritical CO2 utilizing
`the polyethyleneglycol dialkylglycerol and their use for the solubiliza
`tion of hydrophiles , ” Dyes and Pigments , 2005 , 65 : 64-74 .
`Schmidt , C. , “ Therapeutic Interference : Small RNA Molecules Act
`as Blockers of Disease Metabolism , ” Modern Drug Discovery ,
`American Chemical Society , 2003 , pp . 37-42 .
`Sedic . M. et al . ,
`“ Safety Evaluation of Lipid Nanoparticle
`Formulated Modified mRNA in the Sprague - Dawley Rat and
`Cynomolgus Monkey , ” Veterinary Pathology , 2017 : 1-14 , 2017 .
`Semple , S. et al . , “ Immunogenicity and Rapid Blood Clearance of
`Liposomes Containing Polyethylene Glycol - Lipid Conjugates and
`Nucleic Acid , ” The Journal of Pharmacology and Experimental
`Therapeutics , 312 ( 3 ) : 1020-1026 , 2006 .
`Semple , S. et al . ,
`“ Rational Design of Cationic Lipids for siRNA
`Delivery , ” Nature Biotechnology , 28 ( 2 ) : 172-176 , 2010 .
`Semple , S. et al . , “ Supplementary Text and Figures , Supplementary
`Fig . 1 , Supplementary Tables 1-4 and Supplementary Syntheses 1
`and 2 to Rational Design of Cationic Lipids for siRNA Delivery , "
`Nature Biotechnology , 28 ( 2 ) : 172-176 , 2010 , published online at
`https://www.nature.com/articles/nbt.1602 ? draft =
`collection # supplementary - information , last visited on Nov. 14 , 2019 ,
`19 pages .
`Shin , J. et al . “ Acid - triggered release via dePEGylation of DOPE
`liposomes containing acid - labile vinyl ether PEG - lipids , ” Journal of
`Controlled Release , 91 : 187-200 , 2003 .
`Song , L. et al . , “ Characterization of the inhibitory effect of PEG
`lipid conjugates on the intracellular delivery of plasmid and anti
`sense DNA mediated by cationic lipid liposomes , ” Biochimica et
`Biophysica Acta , 1558 : 1-13 , 2002 .
`Sorensen , D. et al . , “ Gene silencing by systemic delivery of syn
`thetic siRNAs in adult mice ” , J. Biol . Chem . , 327 : 761-766 , 2003 .
`Spagnou , S. et al . , “ Lipidic carriers of siRNA : differences in the
`formulation , cellular uptake , and delivery with plasmid DNA , ”
`Biochemistry , 43 : 13348-56 , 2004 .
`Stamatatos , L. et al . , “ Interactions of cationic lipid vesicles with
`negatively charged phospholipid vesicles and biological mem
`branes , ” Biochemistry , 27 : 3917-3925 , 1988 .
`
`

`

`US 11,141,378 B2
`Page 5
`
`( 56 )
`
`References Cited
`OTHER PUBLICATIONS
`Szoka , F. et al . , “ Comparative properties and methods of preparation
`of lipid vesicles ( liposomes ) , ” Ann . Rev. Biophys . Bioeng . , 9 : 467
`508 , 1980 .
`Szoka , F. et al . , “ Procedure for preparation of liposomes with large
`internal aqueous space and high capture by reverse - phase evapo
`ration , ” Proc . Natl . Acad . Sci . USA , 75 ( 9 ) : 4194-98 , 1978 .
`Tam P. et al . , “ Stabilized plasmid - lipid particles for systemic gene
`therapy , ” Gene Therapy , 7 : 1867-74 , 2000 .
`Templeton , N. , “ Cationic liposome - mediated gene delivery in vivo ” ,
`Bioscience Reports , 22 ( 2 ) : 283-295 , 2002 .
`Timmerman , L. “ Merck's Alan Sachs , on RNAi's Big Challenge :
`Delivery , Delivery , Delivery , ” Xconomy , Inc. , https://xconomy.com/
`national / 2010 / 01 / 21 / mercks - alan - sachs - on - mais - big - challenge
`delivery - delivery - delivery -2016- , last visited on Jan. 21 , 2010 , 9
`pages .
`U.S. Department of Health and Human Services , “ Liposome Drug
`Products : Chemistry , Manufacturing , and Controls ; Human
`Pharmacokinetics and Bioavailability ; and Labeling Documenta
`tion , Guidance for Industry , " Food and Drug Administration , Center
`for Drug Evaluation and Research ( CDER ) , Apr. 2018 , 18 pages .
`U.S. Food and Drug Administration , “ FDA Approves First - of - its
`Kind Targeted RNA - based Therapy to Treat a Rare Disease , ” Press
`Announcement , https://www.fda.gov/newsevents/newsroom/
`pressannouncements / ucm616518.htm , Aug. 10 , 2018 , 3 pages .
`U.S. Food and Drug Administration , “ Orange Book : Approved
`Drug Products with Therapeutic Equivalence Evaluations , Patent
`and Exclusivity for : N210922 , " available at https : //www.accessdata .
`
`> >
`
`?
`
`fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_
`No = 210922 & Appl_type = N , last visited Dec. 19 , 2018 , 3 pages .
`U.S. Patent and Trademark Office , Patent Trial and Appeal Board ,
`Inter Partes Review of U.S. Pat . No. 9,364,435 B2 , Case No.
`IPR 2018-00739 , Final Written Decision , Sep. 11 , 2019 , pp . 1-52 .
`Uyechi - O'Brien , L. and Szoka , F. , “ Mechanisms for Cationic Lipids
`in Gene Transfer , ” Pharmaceutical Gene Delivery Systems , Marcel
`Dekker , Inc. , vol . 131 , pp . 79-108 , 2003 .
`Van Der Woude , I. et al . , “ Parameters influencing the introduction
`of plasmid DNA into cells by the use of synthetic amphiphiles as a
`carrier system , ” Biochimica et Biophysica Acta , 1240 : 34-40 , 1995 .
`Wheeler , J. et al . , “ Stabilized plasmid - lipid particles : constructions
`and characterization , ” Gene Therapy , 6 : 271-281 , 1999 .
`Wilson , R. et al . , " Counterion - induced condensation of deoxyribo
`nucleic acid , ” A Light - Scattering Study , Biochemistry , 18 ( 11 ) : 2192
`96 , 1979 .
`Woodle , M. et al . , “ Versatility in lipid compositions showing
`prolonged circulation with sterically stabilized liposomes , ” Biochimica
`et Biophysica Acta , 1105 : 193-200 , 1992 .
`Yew , N.S. and Scheule , R.K. , “ Toxicity of cationic lipid - DNA
`complexes , ” Advances in Genetics , 53 : 189-214 , 2005 .
`Zhang , P. et al . ,
`“ Use of small RNA as antiaging cosmeceuticals , "
`J. Cosmetic Sci . , 64 ( 6 ) : 455-68 , 2013 ( Abstract only ) .
`Zhu , N. et al . , “ Systemic gene expression after intravenous DNA
`delivery into adult mice , ” Science , 261 : 209-211 , 1993 .
`Zimmermann , T. et al , “ RNAi - mediated gene silencing in non
`human primates , " Nature , Nature Publishing Group , London , GB ,
`441 ( 7089 ) : 111-114 , 2006 .
`* cited by examiner
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 6 of 77
`
`

`

`U.S. Patent
`
`Oct. 12. 2021
`
`Sheet 1 of 24
`
`US 11,141,378 B2
`
`Sample 1 Sample 2
`Sample 5
`Sample 7 Sample 8
`* Sample 3 not find Sample 4
`
`from Sample 6
`
`
`
`100
`
`FIG . 1A
`
`10
`
`
`
`nM Total siRNA
`
`
`
`
`
`Activity of SNALP on HT29 Cell Line
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 7 of 77
`
`1
`
`0.8
`0.6
`1.2 1
`
`) Cells Untreated Viability ( %
`
`
`0.2
`
`
`0
`
`
`
`

`

`U.S. Patent
`
`Oct. 12. 2021
`
`Sheet 2 of 24
`
`US 11,141,378 B2
`
`Sample 13 + Sample 14 Sample 15 Sample 16
`Sample 10 * Sample 11 word in Sample 12
`
`the Sample 9
`
`100
`
`FIG . 1B
`
`10
`
`
`
`nM Total siRNA
`
`
`
`
`
`Activity of SNALP on HT29 Cell Line
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 8 of 77
`
`1.2 1 0.8
`0.6
`0.2
`0.4
`
`
`
`
`
`) Cells Untreated Viability ( %
`
`1
`0
`
`

`

`U.S. Patent
`
`Oct. 12. 2021
`
`Sheet 3 of 24
`
`US 11,141,378 B2
`
`Activity of SNALP Upon Intravenous Administration in Mice
`group mean SD ( n = 4 )
`
`2.5
`
`Ratio
`mRNA
`
`Liver ApoB : GAPD
`
`2.0
`
`1.5
`
`10
`
`0.5
`
`0.0
`
`PBS Group 2 Group 3 Group 4 Group 5 Group 6 Group 8 Group 9 Group 10 Group 11 Group 12 Group 13 Group 14
`Group 7
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 9 of 77
`
`FIG . 2
`
`

`

`U.S. Patent
`
`Oct. 12. 2021
`
`Sheet 4 of 24
`
`US 11,141,378 B2
`
`3.0
`
`2.5
`
`2.04
`
`
`
`Liver ApoB : GAPD MRNA Ratio 1.5
`
`
`
`
`
`-47 % vs PBS Control
`
`-77 % VS PBS Control
`
`PBS
`
`2:30 SNALP 5x1 mg / kg 1:57 SNALP 5x0.1 mg / kg
`
`1.0
`
`0.5
`
`0.04
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 10 of 77
`
`FIG . 3
`
`

`

`U.S. Patent
`
`Oct. 12. 2021
`
`Sheet 5 of 24
`
`US 11,141,378 B2
`
`Activity of SNALP Upon Intravenous Administration in Mice
`group mean I SD ( n = 4 )
`
`2.0
`
`1.5
`
`
`
`Liver ApoB : GAPD mRNA Ratio 1.0
`
`
`
`
`
`0.5
`
`0.0+ PBS Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 11 of 77
`
`FIG . 4
`
`

`

`U.S. Patent
`
`Oct. 12. 2021
`
`Sheet 6 of 24
`
`US 11,141,378 B2
`
`Activity of SNALP Upon Intravenous Administration in Mice
`group mean I SD ( n = 4 )
`
`2.0
`
`1.5
`
`Ratio
`mRNA
`ADOB : GAPD
`Liver
`
`1.0
`
`0.5
`
`0.0 PBS Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10 Group 11 Group 12 Group 13 Group 14 Group 15
`
`Case 1:22-cv-02229-MKV Document 1-9 Filed 03/18/22 Page 12 of 77
`
`FIG . 5
`
`

`

`U.S. Patent
`
`Oct. 12 , 2021
`
`Sheet 7 of 24
`
`US 11,141,378 B2
`
`Tolerability of IV 1:57 SNALP in Female BALBIC Mice , 1-4 , SD error
`205
`168
`Alanine Aminotransferase
`Aspartate Aminotransferase
`Sorbital Dehydrogenase
`Incr'd SDH , ALT levels indicate hepatocyte damage .
`96
`
`140
`
`120
`
`100
`
`IUL
`
`80
`
`60
`
`40
`
`20
`
`81
`
`46
`
`53
`
`50
`
`40
`
`23
`
`27
`
`69
`
`59
`
`33
`
`27
`
`79
`
`62
`
`58
`
`35
`
`0
`
`Syringe PBS
`Syringe PBS
`Syringe Citrate
`Syringe Citrate
`PBS
`Gear PBS 9mg / kg
`Gear PBS
`7mg / kg
`9mg / kg 9mg / kg
`7mg / kg 7mg / kg
`FIG . 6A
`
`Tolerability of IV 1:57 SNALP